openmedical/registry
← opportunities

Enzymes and reagents produced where they are used

editorial

Manufacturing & Supply · early attempts · hardest part: manufacturing, distribution, capital

A diagnostic test is mostly reagent cost, and reagents are imported, cold-chained, and priced far above production cost. Local enzyme production is a solved science with no distribution.

This is editorial, not a record. Registry entries are cited facts about things that exist; an opportunity is our argument about something that does not. The links to existing work are checked against the catalog — the judgment around them is ours, and you should disagree with it where you know better.

why it stays closed

Molecular diagnostics depend on a handful of enzymes — polymerases, reverse transcriptases, ligases — sold as purified proteins with large margins and a cold chain attached. The sequences are largely public and the expression protocols are published; the cost structure is dominated by purification, quality control, and shipping rather than by discovery.

what is missing

Not the science. What is missing is a production package: strains, expression and purification protocols validated outside their originating lab, an assay to prove each batch works, and the quality documentation to make a clinician willing to use it. The gap is between "a paper shows this works" and "a technician in another country can make a trustworthy batch on a Tuesday".

who this is for

Every laboratory whose test volume is capped by reagent budget and import logistics, which during an outbreak becomes the constraint on knowing what is happening.

what already exists · 1
  • OpentronsverifiedApache-2.0

    Software for authoring and running protocols on Opentrons liquid-handling laboratory robots.

sources

None cited. Everything above is either reasoning about market structure or a claim you should check yourself. Where we could not source a number, we left it out rather than estimating one.

Last revised 2026-08-05.